Ardelyx Inc Drug Patent Portfolio
Ardelyx Inc owns 2 orange book drugs protected by 7 US patents Given below is the list of Ardelyx Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10272079 | NHE3-binding compounds and methods for inhibiting phosphate transport | 10 Apr, 2034 | Active |
| US10940146 | NHE3-binding compounds and methods for inhibiting phosphate transport | 10 Apr, 2034 | Active |
| US8541448 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | 01 Aug, 2033 | Active |
| US9006281 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | 02 May, 2030 | Active |
| US12016856 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | 30 Dec, 2029 | Active |
| US8969377 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | 30 Dec, 2029 | Active |
| US9408840 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | 30 Dec, 2029 | Active |
Latest Legal Activities on Ardelyx Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ardelyx Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 09 Feb, 2024 | US9408840 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 31 Oct, 2022 | US10272079 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 14 Oct, 2022 | US9006281 |
|
Patent Term Extension Certificate
Critical
| 06 Oct, 2022 | US8541448 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 06 Sep, 2022 | US8969377 |
| Notice of Final Determination -Eligible | 20 Jul, 2022 | US8541448 |
| Notice of Final Determination -Eligible | 14 Jul, 2022 | US8541448 |
|
FDA Final Eligibility Letter
Critical
| 17 Feb, 2022 | US8541448 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 24 Mar, 2021 | US8541448 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Mar, 2021 | US10940146 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Mar, 2021 | US10940146 |
|
Email Notification
Critical
| 18 Feb, 2021 | US10940146 |
|
Issue Notification Mailed
Critical
| 17 Feb, 2021 | US10940146 |
| Dispatch to FDC | 10 Feb, 2021 | US10940146 |
| transaction for FDA Determination of Regulatory Review Period | 08 Feb, 2021 | US8541448 |
Ardelyx Inc's Family Patents
Ardelyx Inc drugs have patent protection in a total of 21 countries. It's US patent count contributes only to 31.1% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Ardelyx Inc Drug List
Given below is the complete list of Ardelyx Inc's drugs and the patents protecting them.
1. Ibsrela
Ibsrela is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8541448 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
01 Aug, 2033
(8 years from now)
| Active |
| US9006281 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
02 May, 2030
(5 years from now)
| Active |
| US12016856 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
30 Dec, 2029
(4 years from now)
| Active |
| US8969377 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
30 Dec, 2029
(4 years from now)
| Active |
| US9408840 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
30 Dec, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ibsrela's drug page
2. Xphozah
Xphozah is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10272079 | NHE3-binding compounds and methods for inhibiting phosphate transport |
10 Apr, 2034
(8 years from now)
| Active |
| US10940146 | NHE3-binding compounds and methods for inhibiting phosphate transport |
10 Apr, 2034
(8 years from now)
| Active |
| US8541448 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
01 Aug, 2033
(8 years from now)
| Active |
| US12016856 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
30 Dec, 2029
(4 years from now)
| Active |
| US8969377 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
30 Dec, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xphozah's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List